Transgene and BioInvent Announce Compelling Preclinical Data For BT-001 in Solid Tumors
(WorldNews France)

Transgene and BioInvent Announce Compelling Preclinical Data For BT-001 in Solid Tumors 11 Dec 2019 08:15 CET Company Name TRANSGENE ISN FR0005175080 Market Euronext Symbol TNG BT-001 is a novel Invir.IO® based oncolytic virus expressing a Treg-depleting anti-CTLA4 antibody and the cytokine GM-CSF Broad antitumor activity shown in immunocompetent models sensitive or resistant to immune checkpoint blockade Regulatory submission for first clinical trial in Europe and US in H1 2020 Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and BioInvent International AB (OMXS: BINV), a biotech company focused on...